Amsterdam UMC, University of Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam, the Netherlands.
Amsterdam UMC, University of Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam, the Netherlands; Department of Clinical Neurophysiology, St Antonius Hospital, Nieuwegein, the Netherlands.
J Neuroimmunol. 2023 Sep 15;382:578169. doi: 10.1016/j.jneuroim.2023.578169. Epub 2023 Aug 4.
B-cell activating factor (BAFF) is a crucial cytokine for differentiation and survival of B-cells and correlates to disease activity in some auto-immune diseases. To evaluate BAFF as a biomarker for disease activity in chronic inflammatory demyelinating polyneuropathy (CIDP), serum BAFF levels were measured at varying disease stages: patients starting treatment, patients starting treatment withdrawal, patients in remission and healthy controls. Serum BAFF levels were elevated in patients compared to healthy controls, but did not differ between patients starting treatment and patients in remission. Serum BAFF levels did not change with or predict treatment response or relapse. Serum BAFF is not a responsive biomarker reflecting disease activity in CIDP.
B 细胞激活因子（BAFF）是 B 细胞分化和存活的关键细胞因子，与某些自身免疫性疾病的疾病活动相关。为了评估 BAFF 作为慢性炎症性脱髓鞘性多发性神经病（CIDP）疾病活动的生物标志物，在不同疾病阶段测量了血清 BAFF 水平：开始治疗的患者、开始治疗停药的患者、缓解期的患者和健康对照者。与健康对照组相比，患者的血清 BAFF 水平升高，但开始治疗的患者与缓解期的患者之间无差异。血清 BAFF 水平的变化与治疗反应或复发无关，也不能预测治疗反应或复发。血清 BAFF 不是反映 CIDP 疾病活动的响应性生物标志物。
